Last update :
19/11/2024
InfoStab
Infostab
List of drugs
List of drugs
Summary lists
Summary lists
Search for compatibilities
Search for compatibilities
Y-site compatibility table
Y-site compatibility table
References
References
Research teams
Research teams
valistab
valistab
Poster
Poster
Links
Links
Sponsors
Sponsors
Authors
Authors
User’s guide
User’s guide
Newsletter
Newsletter
Anticancer drug   Ipilimumab  
injection
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References pdf

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers
Yervoy Argentina, Australia, Belgium, Canada, Chile, Colombia, Denmark, France, Germany, Great Britain, Iceland, Ireland, Italy, Mexico, Norway, Poland, Portugal, Romania, Slovenia, Spain, Sweden, Switzerland, Turkey, United States of America
References   injection   References : Ipilimumab  
Type Publication
2296 Manufacturer Témocilline (Negaban®) - Résumé des caractéristiques du produit
Eumedica 2017
3352 Manufacturer Ipilimumab (Yervoy®) - Summary of Product Characteristics
Bristol Myers Squibb 2011
3446 Poster Bardo P, Vieillard V, Astier A, Paul M.
Stabilité physicochimique de solutions diluées d'ipilimumab : résultats préliminaires à 1 mois.
SFPO Congress, Mandelieu, France 2013
3850 Journal Bardo-Brouard P, Vieillard V, Shekarian T, Marabelle A, Astier A, Paul M.
Stability of ipilimumab in its original vial after opening allows its use for at least 4 weeks and facilitates pooling of residues.
Eur J Cancer 2016 ; 58: 8-16.
  Mentions Légales